Lauromicina

Lauromicina may be available in the countries listed below.

Ingredient matches for Lauromicina

Erythromycin

Erythromycin stearate (a derivative of Erythromycin) is reported as an ingredient of Lauromicina in the following countries:

• Italy

International Drug Name Search

Fluconazol Redibag Baxter

Fluconazol Redibag Baxter may be available in the countries listed below.

Ingredient matches for Fluconazol Redibag Baxter

Fluconazole

Fluconazole is reported as an ingredient of Fluconazol Redibag Baxter in the following countries:

• Slovakia


• Switzerland

International Drug Name Search

Paxil

See also: Generic Paxil CR

Paxil is a brand name of paroxetine, approved by the FDA in the following formulation(s):

PAXIL (paroxetine hydrochloride - suspension; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: June 25, 1997
  
  Strength(s): EQ 10MG BASE/5ML ^[RLD][AB]

PAXIL (paroxetine hydrochloride - tablet; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: December 29, 1992
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 20MG BASE ^[AB], EQ 30MG BASE ^[AB], EQ 40MG BASE ^[RLD][AB]

Has a generic version of Paxil been approved?

A generic version of Paxil has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Paxil and have been approved by the FDA:

paroxetine hydrochloride suspension; oral

• 
  Manufacturer: APOTEX INC
  
  Approval date: December 5, 2006
  
  Strength(s): EQ 10MG BASE/5ML ^[AB]

paroxetine hydrochloride tablet; oral

• 
  Manufacturer: ALPHAPHARM
  
  Approval date: March 8, 2004
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 20MG BASE ^[AB], EQ 30MG BASE ^[AB], EQ 40MG BASE ^[AB]


• 
  Manufacturer: APOTEX
  
  Approval date: July 30, 2003
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 20MG BASE ^[AB], EQ 30MG BASE ^[AB], EQ 40MG BASE ^[AB]


• 
  Manufacturer: AUROBINDO PHARMA
  
  Approval date: July 25, 2007
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 20MG BASE ^[AB], EQ 30MG BASE ^[AB], EQ 40MG BASE ^[AB]


• 
  Manufacturer: CARACO
  
  Approval date: June 29, 2007
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 20MG BASE ^[AB], EQ 30MG BASE ^[AB], EQ 40MG BASE ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: March 13, 2008
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 20MG BASE ^[AB], EQ 30MG BASE ^[AB], EQ 40MG BASE ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: August 15, 2005
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 20MG BASE ^[AB], EQ 30MG BASE ^[AB], EQ 40MG BASE ^[AB]


• 
  Manufacturer: ZYDUS PHARMS USA
  
  Approval date: March 7, 2007
  
  Strength(s): EQ 10MG BASE ^[AB], EQ 20MG BASE ^[AB], EQ 30MG BASE ^[AB], EQ 40MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Paxil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Oral liquid compositions containing paroxetine resinate
  Patent 5,811,436
  Issued: September 22, 1998
  Inventor(s): Leonard; Graham Stanley & Cooper; David
  Assignee(s): SmithKline Beecham plc
  An oral liquid pharmaceutical composition comprising a paroxetine-Amberlite IRP88 complex.
  
  Patent expiration dates:
  
  
  • September 22, 2015
    
  
  
  
  • March 22, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Form of paroxetine hydrochloride anhydrate
  Patent 5,872,132
  Issued: February 16, 1999
  Inventor(s): Ward; Neal & Jacewicz; Victor Witold
  Assignee(s): SmithKline Beecham Corporation
  "Paroxetine hydrochloride (I) anhydrate ##STR1## free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
  
  Patent expiration dates:
  
  
  • May 19, 2015
    
  
  
  
  • November 19, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Form of paroxetine hydrochloride anhydrate
  Patent 5,900,423
  Issued: May 4, 1999
  Inventor(s): Ward; Neal & Jacewicz; Victor Witold
  Assignee(s): SmithKline Beecham Corporation
  "Paroxetine hydrochloride (I) anhydrate ##STR1## free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
  
  Patent expiration dates:
  
  
  • May 19, 2015
    
  
  
  
  • November 19, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Component arrangement for outboard motor
  Patent 6,062,927
  Issued: May 16, 2000
  Inventor(s): Hiraoka; Noriyoshi & Takahashi; Masanori
  Assignee(s): Sanshin Kogyo Kabushiki Kaisha
  This invention is an outboard motor for use in propelling a watercraft. The motor has a cowling in which is positioned an internal combustion engine. The internal combustion engine comprises a V shaped cylinder block cooperating with first and second cylinder heads to define first and second cylinder banks. The cylinder banks form a valley therebetween. Each of the cylinder banks include at least one combustion chamber. A crankcase is located at an end of the block opposite the heads forming a crankcase chamber. The engine also includes an exhaust system for routing the products of combustion from at least one combustion chamber and an intake system for providing air to the at least one combustion chamber. The intake system includes a single surge tank positioned between the cowling and the crankcase of the engine. At least one first intake pipe extends from the surge tank in a first direction along the cylinder block to the first cylinder head and at least one second intake pipe extends along the cylinder block to the second cylinder head.
  
  Patent expiration dates:
  
  
  • April 23, 2019
    
  
  



• 
  Paroxetine derivatives
  Patent 6,063,927
  Issued: May 16, 2000
  Inventor(s): Craig; Andrew Simon & Jones; Alan David & O'Keeffe; Deirdre & Ward; Neal
  Assignee(s): SmithKline Beecham plc
  Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.
  
  Patent expiration dates:
  
  
  • April 23, 2019
    
  
  
  
  • October 23, 2019
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Paroxetine hydrochloride form A
  Patent 6,080,759
  Issued: June 27, 2000
  Inventor(s): Ward; Neal & Jacewicz; Victor Witold
  Assignee(s): SmithKline Beecham Corporation
  "Paroxetine hydrochloride (I) anhydrate free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
  
  Patent expiration dates:
  
  
  • May 19, 2015
    
  
  
  
  • November 19, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Paroxetine tablets and process to prepare them
  Patent 6,113,944
  Issued: September 5, 2000
  Inventor(s): Pathak; Ram Dutta & Doughty; David George
  Assignee(s): SmithKline Beecham p.l.c.
  Invented is a novel pharmaceutical composition containing Paroxetine.
  
  Patent expiration dates:
  
  
  • December 14, 2014
    
  
  
  
  • June 14, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
  Patent 6,121,291
  Issued: September 19, 2000
  Inventor(s): Gleason; Maurice
  Assignee(s): SmithKline Beecham plc
  This invention relates to the use of paroxetine or a pharmaceutically acceptable salt thereof for the treatment of post-traumatic stress disorder and depression associated with withdrawal from heroin abuse.
  
  Patent expiration dates:
  
  
  • March 17, 2017
    
    ✓ 
    Patent use: POSTTRAUMATIC STRESS DISORDER
  
  
  
  • March 17, 2017
    
    ✓ 
    Patent use: DEPRESSION
  
  
  
  • September 17, 2017
    
    ✓ 
    Patent use: POSTTRAUMATIC STRESS DISORDER
    ✓ 
    Pediatric exclusivity
  
  
  
  • September 17, 2017
    
    ✓ 
    Patent use: DEPRESSION
    ✓ 
    Pediatric exclusivity
  
  



• 
  Paroxetine hydrochloride form A or C
  Patent 6,133,289
  Issued: October 17, 2000
  Inventor(s): Ward; Neal & Jacewicz; Victor Witold
  Assignee(s): SmithKline Beecham Corporation
  Invented are methods of treatment using novel forms of paroxetine hydrochloride anhydrate.
  
  Patent expiration dates:
  
  
  • May 19, 2015
    
    ✓ 
    Patent use: DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
  
  
  
  • November 19, 2015
    
    ✓ 
    Patent use: DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
    ✓ 
    Pediatric exclusivity
  
  



• 
  Process for making paroxetine
  Patent 6,172,233
  Issued: January 9, 2001
  Inventor(s): Ward; Neal
  Assignee(s): SmithKline Beecham plc
  Compounds of structure (2) are prepared by reaction of an arecoline analogue of structure(4) with an organometallic compound containing an X-substituted phenyl group, such as a compound of structure (3). ##STR1## Suitably the compound of structure (3) is a Grignard reagent, where M is magnesium and Y is a halogen atom, or M may be a Group II metal and Y is a halogen atom or a second X-substituted phenyl group. When structure (3) is a Grignard reagent, the reaction is carried out either in a suitable non-ether solvent, typically a hydrocarbon or a non-reactive chlorinated hydrocarbon, or in a mixture of such a solvent with diethyl ether. Compounds of structure (2) are important intermediates in the preparation of inter alia paroxetine.
  
  Patent expiration dates:
  
  
  • January 15, 2018
    
  
  
  
  • July 15, 2018
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Paxil Consumer Information (Drugs.com)
• Paxil Consumer Information (Wolters Kluwer)
• Paxil Suspension Consumer Information (Wolters Kluwer)
• Paxil Consumer Information (Cerner Multum)
• Paxil Advanced Consumer Information (Micromedex)
• Paxil AHFS DI Monographs (ASHP)
• Paroxetine Consumer Information (Drugs.com)
• Paroxetine Consumer Information (Wolters Kluwer)
• Paroxetine Controlled-Release Tablets Consumer Information (Wolters Kluwer)
• Paroxetine Mesylate Consumer Information (Wolters Kluwer)
• Paroxetine Suspension Consumer Information (Wolters Kluwer)
• Paroxetine Consumer Information (Cerner Multum)
• Paroxetine Advanced Consumer Information (Micromedex)
• Paroxetine Hydrochloride AHFS DI Monographs (ASHP)

Flumazénil Kabi

Flumazénil Kabi may be available in the countries listed below.

Ingredient matches for Flumazénil Kabi

Flumazenil

Flumazenil is reported as an ingredient of Flumazénil Kabi in the following countries:

• France

International Drug Name Search

Olopatadine Hydrochloride

Class: Antiallergic Agents
ATC Class: S01GX09
VA Class: OP900
Chemical Name: 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride
Molecular Formula: C₂₁H₂₃NO₃•HCl
CAS Number: 140462-76-6
Brands: Patanol

Introduction

Relatively selective histamine H₁-receptor antagonist^{1 2 3 4 5 6} and mast-cell stabilizer.^{1 2 3 4 5 6 b}

Uses for Olopatadine Hydrochloride

Allergic Conjunctivitis

Temporary prevention of ocular itching associated with allergic conjunctivitis.^{1 2 13}

Olopatadine Hydrochloride Dosage and Administration

Administration

Ophthalmic Administration

Apply topically to the eye as an ophthalmic solution.¹ Not for injection or oral use.¹

If more than one topical ophthalmic drug is used, administer the drugs at least 5 minutes apart.¹²

Avoid contamination of the solution container.¹

Dosage

Available as olopatadine hydrochloride; dosage expressed in terms of olopatadine.¹

Pediatric Patients

Allergic Conjunctivitis

Ophthalmic

Children ≥3 years of age: 1 or 2 drops of a 0.1% solution in the affected eye(s) twice daily (at an interval of 6–8 hours).¹

Once symptomatic improvement is established, continue therapy for as long as necessary to sustain improvement.¹²

Adults

Allergic Conjunctivitis

Ophthalmic

1 or 2 drops of a 0.1% solution in the affected eye(s) twice daily (at an interval of 6–8 hours).¹

Once symptomatic improvement is established, continue therapy for as long as necessary to sustain improvement.¹²

Cautions for Olopatadine Hydrochloride

Contraindications

• 
  

  Known hypersensitivity to olopatadine or any ingredient in the formulation.¹

  
  

Warnings/Precautions

Specific Populations

Pregnancy

Category C.¹

Lactation

Distributed into milk in rats following oral administration;¹ not known whether distributed into human milk following topical application to the eye.¹ Use with caution.¹

Pediatric Use

Safety and efficacy not established in children <3 years of age.¹

Appears to be well-tolerated in children 3–16 years of age.^{11 13}

Geriatric Use

No substantial differences in safety and efficacy relative to younger adults.^a

Common Adverse Effects

Headache.^{1 2 13}

Interactions for Olopatadine Hydrochloride

No formal drug interaction studies to date.¹²

Olopatadine Hydrochloride Pharmacokinetics

Absorption

Bioavailability

Limited systemic exposure following topical application to the eye;¹ plasma concentrations usually are undetectable.^{1 12 13}

Onset

Rapid onset;^{3 13 14 15} symptomatic relief of itching generally occurs within 30 minutes.^{12 13 15}

Duration

Long duration (≥8 hours).^{3 13 14 15}

Distribution

Extent

Distribution into human ocular tissues and fluids not characterized.¹

Elimination

Metabolism

Metabolized in the liver to monodesmethyl olopatadine and olopatadine N-oxide following topical application to the eyes.^{1 12}

Elimination Route

Eliminated principally by renal excretion; 60–70% of systemically absorbed dose excreted in urine as parent drug.^{1 12}

Half-life

Approximately 3 hours following topical application to the eyes.¹

Stability

Storage

Ophthalmic

Solution

4–25°C.¹

ActionsActions

• 
  

  Inhibits type I immediate hypersensitivity reactions in vitro and in vivo.^{1 3}

  
  


• 
  

  Suppresses the release of inflammatory mediators (e.g., histamine, prostaglandin D₂, tryptase) in response to antigenic stimulation of human conjunctival mast cells in a dose-dependent manner.^{5 13}

  
  


• 
  

  Inhibits histamine-stimulated conjunctival vascular permeability response in a concentration-dependent manner.³

  
  


• 
  

  Potency is comparable to that of levocabastine and exceeds that of pheniramine or antazoline.^{3 13}

  
  

Advice to Patients

• 
  

  Importance of learning and adhering to proper administration techniques to avoid contamination of the solution container.^{1 12}

  
  


• 
  

  Importance of removing soft contact lenses prior to administration of each dose.¹ Delay reinsertion for 10 minutes after administration if eyes are not red; do not wear contact lenses if eye(s) are red.^{1 12} Not indicated for contact lens-related irritation.¹

  
  


• 
  

  Importance of administering different topical ophthalmic preparations at least 5 minutes apart.¹²

  
  


• 
  

  Importance of patients informing clinicians of exisiting or contemplated therapy, including prescription and OTC drugs.

  
  


• 
  

  Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.^a

  
  


• 
  

  Importance of informing patients of other important precautionary information.^a (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Olopatadine Hydrochloride

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Ophthalmic	Solution	0.1% (of olopatadine)	Patanol (with benzalkonium chloride)	Alcon

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Pataday 0.2% Solution (ALCON VISION): 2/$119.99 or 7/$334.98

Patanol 0.1% Solution (ALCON VISION): 5/$125.99 or 15/$359.99

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions May 2004. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

1. Alcon Laboratories. Patanol (olopatadine hydrochloride) ophthalmic solution 0.1% prescribing information. Fort Worth, TX; 1996 Dec.

2. Anon. Olopatadine for allergic conjunctivitis. Med Lett Drugs Ther. 1997; 39:108-9. [PubMed 9398823]

3. Yanni JM, Stephens DJ, Miller ST et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996; 12:389-400. [PubMed 8951675]

4. Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H₁-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther. 1996; 12:401-7. [PubMed 8951676]

5. Sharif NA, Xu SX, Miller ST et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther. 1996; 278:1252-61. [PubMed 8819509]

6. Kamei C, Sugimoto Y, Nakamura S et al. Effect of (Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs. Arzneimittelforschung. 1995; 45:1005-8. [PubMed 7488300]

7. Ciprandi G, Buscaglia S, Cerqueti PM et al. Drug treatment of allergic conjunctivitis: a review of the evidence. Drugs. 1992; 43:154-76. [IDIS 360840] [PubMed 1372215]

8. Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician. 1998; 57:735-46. [IDIS 418448] [PubMed 9490996]

9. Titi MJ. A critical look at ocular allergy drugs. Am Fam Physician. 1996; 53:2637-42. [IDIS 367250] [PubMed 8644576]

10. Galindez OA, Kaufman HE. Coping with the itchy-burnies: the management of allergic conjunctivitis. Ophthalmology. 1996; 103:1335-6. [IDIS 373485] [PubMed 8841290]

11. Reviewers’ comments (personal observations).

12. Alcon Laboratories; Fort Worth, TX: Personal communication.

13. Alcon Laboratories. Patanol (olopatadine hydrochloride) ophthalmic solution 0.1% product monograph. Fort Worth, TX: (not dated).

14. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol. 1998; 125:797-804. [IDIS 409293] [PubMed 9645717]

15. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol. 1998; 81:211-8. [IDIS 415165] [PubMed 9759796]

a. Alcon Laboratories. Patanol (olopatadine hydrochloride) ophthalmic solution 0.1% prescribing information. Fort Worth, TX; 2003 Dec.

b. Anon. New drugs for allergic conjunctivitis. Med Lett Drugs Ther. 2000; 42:39-40. [PubMed 10825920]

More Olopatadine Hydrochloride resources

• Olopatadine Hydrochloride Dosage
• Olopatadine Hydrochloride Use in Pregnancy & Breastfeeding
• Olopatadine Hydrochloride Support Group
• 17 Reviews for Olopatadine Hydrochloride - Add your own review/rating

Compare Olopatadine Hydrochloride with other medications

• Seasonal Allergic Conjunctivitis

Xylazine

In some countries, this medicine may only be approved for veterinary use.

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0007361-61-7

Chemical Formula

C12-H16-N2-S

Molecular Weight

220

Therapeutic Categories

Sedative agent

Analgesic

Muscle relaxant

Chemical Name

4H-1,3-Thiazin-2-amine, N-(2,6-dimethylphenyl)-5,6-dihydro-

Foreign Names

• Xylazinum (Latin)
• Xylazin (German)
• Xylazine (French)
• Xilazina (Spanish)

Generic Names

• Xylazine (OS: BAN)
• Bayer 1470 (IS)
• Xylazine (PH: USP 32)
• Xylazine Hydrochloride (OS: USAN, BANM)
• Bay Va 1470 (IS)
• Xylazine (chlorhydrate de) pour usage vétérinaire (PH: Ph. Eur. 6)
• Xylazine Hydrochloride (PH: BP vet. 2007, USP 32)
• Xylazine Hydrochloride for Veterinary Use (PH: Ph. Eur. 6)
• Xylazinhydrochlorid für Tiere (PH: Ph. Eur. 6)
• Xylazini hydrochloridum ad usum veterinarium (PH: Ph. Eur. 6)

Brand Names

• Anased (veterinary use)
  Lloyd, New Zealand



• Chanazine (veterinary use)
  Agrovete, Portugal; Bayer Animal Health, South Africa; Chanelle, United Kingdom; Chanelle, Ireland; Chanelle, Netherlands; Chanelle Pharmaceuticals, Austria



• Megaxilor (veterinary use)
  Bio98, Italy



• Phoenix Xylazine (veterinary use)
  Phoenix, New Zealand



• Vetaxilaze (veterinary use)
  Vetlima, Portugal



• Virbaxyl (veterinary use)
  Virbac, United Kingdom



• Xilor (veterinary use)
  Bio98, Italy



• Xylacare (veterinary use)
  Animalcare, United Kingdom



• Xylavet (veterinary use)
  Intervet, South Africa



• Xylaze (veterinary use)
  Bomac, New Zealand



• Xylazin (veterinary use)
  aniMedica, Germany; Medistar, Germany



• Xylazine (veterinary use)
  Millpledge, United Kingdom



• A.A. Xylazine (veterinary use)
  Ceva, Netherlands



• Anased (veterinary use)
  Lloyd, United States



• Bomazine (veterinary use)
  Bomac, New Zealand; Bomac Animal Health, Australia



• Cervizine (veterinary use)
  Lloyd, United States



• Chanazine (veterinary use)
  Chanelle, United States



• Narcoxyl (veterinary use)
  Intervet, Austria; Intervet, Finland; Intervet, Norway; Intervet, Sweden



• Paxman (veterinary use)
  Virbac, France



• Phoenix Xylaket (Xylazine andKetamine (veterinary use))
  Phoenix, New Zealand



• Proxylaz (veterinary use)
  Veyx, Germany



• Rompun (veterinary use)
  Bayer, Sweden; Bayer Animal, Germany; Bayer Animal, Netherlands; Bayer Animal, Norway; Bayer Animal Health, Belgium; Bayer Animal Health, United Kingdom; Bayer Animal Health, South Africa; Bayer Healthcare LLC, United States; Bayer Portugal, SA., Portugal; Bayer Sanità Animale, Italy; Bayer Santé Animale Division Santé Animale, France; Bayer Tiergesundheit, Austria; Orion, Finland; Provet, Switzerland



• Sedamun (veterinary use)
  Eurovet, Netherlands



• Sedaxylan (veterinary use)
  Ceva, France; Eurovet, Austria; Eurovet, Belgium; Eurovet, Italy; Eurovet, Luxembourg; Eurovet, Netherlands; Eurovet, Portugal; Vetem, Italy; WDT, Germany



• Sedazine (veterinary use)
  A.S.T. farma B.V, Netherlands; Fort Dodge Animale Health, United States



• Thiazine (veterinary use)
  Nature Vet, Australia



• Vexylan (veterinary use)
  Ceva, Belgium



• Virbaxyl (veterinary use)
  Virbac, Italy



• Xylalin (veterinary use)
  Alfasan, Netherlands; Ceva, Netherlands



• Xylapan (veterinary use)
  Vetochas, Germany; Vetoquinol, Switzerland; Vetoquinol, United Kingdom



• Xylasan (veterinary use)
  Alfasan, Netherlands



• Xylasel (veterinary use)
  Selecta, Germany



• Xylasol (veterinary use)
  Animedica, Austria; Gräub, Switzerland



• Xylaze (veterinary use)
  Bomac Animal Health, Australia



• Xylazil (veterinary use)
  Ilium Veterinary Products, Australia



• Xylazin Streuli (veterinary use)
  Streuli Vet, Switzerland



• Xylazin (veterinary use)
  Albrecht, Germany; Alvetra, Germany; Ceva, Germany; Riemser Animal, Germany; Serumber, Germany



• Xylazine HCl (veterinary use)
  Boehringer Ingelheim Vetmedica, United States



• Xylazine (veterinary use)
  CP-Pharma, Germany; Dopharma, Netherlands; Kepro, Netherlands



• Xyl-M (veterinary use)
  V.M.D, Belgium

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Benzacne

Benzacne may be available in the countries listed below.

Ingredient matches for Benzacne

Benzoyl Peroxide

Benzoyl Peroxide is reported as an ingredient of Benzacne in the following countries:

• Poland

International Drug Name Search

Omeoformula 3 Tissue Tone

OMEOFORMULA®3-TISSUE TONE (Homeopathic complex preparation) INJECTION SC, ID, IM

1. INDICATIONS AND USAGE

1.1.    Skin slackening

1.2.    Tissue revitalization

1.3.    Gluteal muscle tone.

2. DOSAGE AND ADMINISTRATION

2.1.    Treatment for IM application: 1 vial 1-3 times a week according to severity and clinic evolution.

2.2.    Treatment using mesotherapy technique: Apply 0.3 ml for each point. Using a 13 mm, 30G or a 4 mm, 27G needle, make the classic intradermal injections utilizing mesotherapy technique.

Application points: Apply to the affected area (abdomen, upper and lower extremities, gluteus muscles). Gluteus muscles:  from the center of the gluteus muscle proceed along 4 injection lines, in a sunburst shape; apply along the subgluteal furrow.

Standard protocol consists of one session a week for 5-7 weeks. For prolonged treatments, 2 sessions for the first week, 1 session a week for 1 month and then 1 session a month are recommended.


Discard unused solution.


2.3.    Opening of Vials: Use sterile needles and sterile syringe. Do not reuse. Do not use if foreign particles are present. Draw 1 cc of air into syringe, insert needle into vial inject air and withdraw the solution into the syringe

3. DOSAGE FORMS AND STRENGTHS

3.1.    Injectable solution for subcutaneneous, intradermal, or intramuscular  administration.

Pharmaceutical forms: 2 ml glass vials.

3.2.    Each ingredient is attenuated according to the Homeopathic Pharmacopea of United States.

Active ingredients: a-Ketoglutaricum acidum 6X; Barium oxalosuccinate 6X; Calcarea carbonica 6X; Calcarea carbonica 30X; Calcarea carbonica 200X; Cis-Aconitic acid 6X; Citricum acidum 6X; Cyclamen europaeum 6X; DL malic acid 6X; Embryo  6X; Fumaricum acidum 6X; Funiculus umbilicalis 6X; Isoleucine 6X; Leucine 6X; Lysine 6X; Magnesium gluconate 6X; Manganum phosphoricum 6X; Methionine 6X; Natrum pyruvicum 6X; Natrum sulphuricum 6X; Nicotinamidum 6X; Phenylalanine 6X; Placenta 10X; Pulsatilla 6X; Succinicum acidum 6X; Threonine 6X; Thuja occidentalis 6X; Tryptophan 6X; Valine 6X.

Inactive ingredient: Sterile isotonic sodium chloride solution.

4. CONTRAINDICATIONS

4.1.    There is no history of hypersensitivity to OMEOFORMULA®3-TISSUE TONE. However patients with a known hypersensitivity to any ingredient should be tested before use. Make a spot injection (0.1ml) into the forearm and observe for any reactions for 1 hour.

5. WARNINGS AND PRECAUTIONS

5.1.    Be sure to disinfect the area before application. Skin disinfection helps avoid infection at the site of administration that can result from saprophytic bacteria (i.e. atypical mycobacteria, staphylococcus genus) that may be present on the skin.

6. ADVERSE REACTIONS

6.1.    The most common mild adverse reaction is slight reddening at the injection site due to the mechanical effect of the needle or a superficial skin reaction of mild erythema.

7. DRUG INTERACTIONS

7.1.    None Known.

8. USE IN SPECIFIC POPULATIONS

8.1    Pregnancy:  Pregnancy  category  C.  Animal  reproduction  studies  have  not  been conducted  with  OMEOFORMULA®3-TISSUE TONE.  OMEOFORMULA®3-TISSUE TONE  should  not  be  administered  to  a pregnant woman. 

8.2    Nursing mothers:    It is not known whether any of the ingredients in OMEOFORMULA®3-TISSUE TONE  are  secreted  in  human milk.  However, since many drugs are secreted in human milk, caution should be exercised when OMEOFORMULA®3-TISSUE TONE is administered to a nursing woman.

8.3    Pediatric use: Effectiveness in pediatric patients has not been established.

8.4    Geriatric use: No restrictions.

9. DRUG ABUSE AND DEPENDENCE

9.1.    No Known.

10. OVERDOSAGE

10.1.    No Known.

11. DESCRIPTION

OMEOFORMULA®3- TISSUE TONE is a sterile solution made with isotonic sodium chloride solution. Its formulation is based on classical Homeopathy and each ingredient has been selected according to the homeopathic description as referred to in  Materia Medica.

The firming and toning activity is due to the activity of the suis-organ ingredients.  The amino acid ingredients promote protein synthesis.

12. CLINICAL PHARMACOLOGY

12.1.    Mechanism of Action

The medication acts through a low-dose enzymatic mechanism.

12.2.    Pharmacodynamics

The physiological effects of OMEOFORMULA®3- TISSUE TONE      are  due to  the effects of the ingredients, according to their description in the Homeopathic Materia Medica.

12.3.    Pharmacokinetics

Homeopathic attenuation  provides complete bioavability of the active ingredients.

13. NONCLINICAL TOXICOLOGY

13.1.    OMEOFORMULA®3- TISSUE TONE has no level of toxicity due to the attenuation of the ingredients.

14. CLINICAL STUDIES

14.1.    OMEOFORMULA®3- TISSUE TONE formulation is based  on classical Homeopathy and each ingredient has been selected according to the homeopathic description as referred in Materia Medica.

15. REFERENCES

15.1.    E.Italia, M. De Bellis: Manuale di Omeo-mesoterapia – Guna Ed. 1995

15.2.    H.H. Reckeweg: Homeopathic Materia medica omeopatica. Aurelia Verlag.

16. HOW SUPPLIED/STORAGE AND HANDLING

16.1.    NDC 17089-274-31  10 glass vial packed in carton box

16.2.    NDC 17089-274-32  50 glass vial packed in carton box

16.3.    Store at room temperature, 20-25°C (68-77° F). Avoid  freezing  and  excessive  heat.

17. PATIENT COUNSELING INFORMATION

17.1.    Patients should be informed of the homeopathic approach and the therapeutic goals of OMEOFORMULA®3- TISSUE TONE.

PACKAGE LABEL

OMEOFORMULA 3-TISSUE TONE   .alpha.-ketoglutaric acid - aconitic acid, cis - barium cation - calcium carbonate - citric acid monohydrate - cyclamen purpurascens tuber - fumaric acid - isoleucine - leucine - lysine - magnesium gluconate - malic acid - manganese phosphate, dibasic - methionine - natrum sulphuricum - niacinamide - phenylalanine - pulsatilla vulgaris - sodium pyruvate - succinic acid - sus scrofa placenta - sus scrofa umbilical cord - threonine - thuja occidentalis twig - tryptophan - valine - sus scrofa embryo -   injection, solution

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 17089-274 Route of Administration INTRADERMAL, SUBCUTANEOUS, INTRAMUSCULAR DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength .ALPHA.-KETOGLUTARIC ACID (.ALPHA.-KETOGLUTARIC ACID) .ALPHA.-KETOGLUTARIC ACID 6 [hp_X]  in 2 mL BARIUM OXALOSUCCINATE (BARIUM OXALOSUCCINATE) BARIUM OXALOSUCCINATE 6 [hp_X]  in 2 mL CALCIUM CARBONATE (CALCIUM CATION) CALCIUM CARBONATE 30 [hp_X]  in 2 mL ACONITIC ACID, CIS- (ACONITIC ACID, CIS-) ACONITIC ACID, CIS- 6 [hp_X]  in 2 mL CITRIC ACID MONOHYDRATE (ANHYDROUS CITRIC ACID) CITRIC ACID MONOHYDRATE 6 [hp_X]  in 2 mL CYCLAMEN PURPURASCENS TUBER (CYCLAMEN PURPURASCENS TUBER) CYCLAMEN PURPURASCENS TUBER 6 [hp_X]  in 2 mL MALIC ACID (MALIC ACID) MALIC ACID 6 [hp_X]  in 2 mL SUS SCROFA EMBRYO (SUS SCROFA EMBRYO) SUS SCROFA EMBRYO 6 [hp_X]  in 2 mL FUMARIC ACID (FUMARIC ACID) FUMARIC ACID 6 [hp_X]  in 2 mL SUS SCROFA UMBILICAL CORD (SUS SCROFA UMBILICAL CORD) SUS SCROFA UMBILICAL CORD 6 [hp_X]  in 2 mL ISOLEUCINE (ISOLEUCINE) ISOLEUCINE 6 [hp_X]  in 2 mL LEUCINE (LEUCINE) LEUCINE 6 [hp_X]  in 2 mL LYSINE (LYSINE) LYSINE 6 [hp_X]  in 2 mL MAGNESIUM GLUCONATE (MAGNESIUM CATION) MAGNESIUM GLUCONATE 6 [hp_X]  in 2 mL MANGANESE PHOSPHATE, DIBASIC (MANGANESE PHOSPHATE, DIBASIC) MANGANESE PHOSPHATE, DIBASIC 6 [hp_X]  in 2 mL Methionine (Methionine ) Methionine 6 [hp_X]  in 2 mL SODIUM PYRUVATE (PYRUVIC ACID) SODIUM PYRUVATE 6 [hp_X]  in 2 mL SODIUM SULFATE (SODIUM CATION) SODIUM SULFATE 6 [hp_X]  in 2 mL NIACINAMIDE (NIACINAMIDE) NIACINAMIDE 6 [hp_X]  in 2 mL PHENYLALANINE (PHENYLALANINE) PHENYLALANINE 6 [hp_X]  in 2 mL SUS SCROFA PLACENTA (SUS SCROFA PLACENTA) SUS SCROFA PLACENTA 10 [hp_X]  in 2 mL PULSATILLA VULGARIS (PULSATILLA VULGARIS) PULSATILLA VULGARIS 6 [hp_X]  in 2 mL SUCCINIC ACID (SUCCINIC ACID) SUCCINIC ACID 6 [hp_X]  in 2 mL THREONINE (THREONINE) THREONINE 6 [hp_X]  in 2 mL THUJA OCCIDENTALIS TWIG (THUJA OCCIDENTALIS TWIG) THUJA OCCIDENTALIS TWIG 6 [hp_X]  in 2 mL TRYPTOPHAN (TRYPTOPHAN) TRYPTOPHAN 6 [hp_X]  in 2 mL VALINE (VALINE) VALINE 6 [hp_X]  in 2 mL

Inactive Ingredients Ingredient Name Strength SODIUM CHLORIDE 0.018 mL  in 2 mL WATER

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 17089-274-31 10 VIAL In 1 BOX contains a VIAL, GLASS 1 2 mL In 1 VIAL, GLASS This package is contained within the BOX (17089-274-31) 2 17089-274-32 50 VIAL In 1 BOX contains a VIAL, GLASS 2 2 mL In 1 VIAL, GLASS This package is contained within the BOX (17089-274-32)

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved homeopathic		09/29/2006

Labeler - Guna spa (430538264)

Establishment
Name	Address	ID/FEI	Operations
Guna spa		430538264	manufacture

Revised: 06/2010Guna spa

Uralyt Urato

Uralyt Urato may be available in the countries listed below.

Ingredient matches for Uralyt Urato

Potassium Citrate

Potassium Citrate is reported as an ingredient of Uralyt Urato in the following countries:

• Spain

International Drug Name Search

Zuracyn

Zuracyn may be available in the countries listed below.

Ingredient matches for Zuracyn

Erythromycin

Erythromycin is reported as an ingredient of Zuracyn in the following countries:

• Bangladesh

International Drug Name Search

Armolev

Armolev may be available in the countries listed below.

Ingredient matches for Armolev

Levofloxacin

Levofloxacin is reported as an ingredient of Armolev in the following countries:

• Indonesia

International Drug Name Search

Juvisync

Juvisync is a brand name of simvastatin/sitagliptin, approved by the FDA in the following formulation(s):

JUVISYNC (simvastatin; sitagliptin phosphate - tablet; oral)

• 
  Manufacturer: MERCK SHARP DOHME
  
  Approval date: October 7, 2011
  
  Strength(s): 10MG;EQ 100MG BASE, 20MG;EQ 100MG BASE, 40MG;EQ 100MG BASE ^[RLD]

Has a generic version of Juvisync been approved?

No. There is currently no therapeutically equivalent version of Juvisync available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Juvisync. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
  Patent 6,303,661
  Issued: October 16, 2001
  Inventor(s): Demuth; Hans-Ulrich & Rosche; Fred & Schmidt; Joem & Pauly; Robert P. & McIntosh; Christopher H. S. & Pederson; Ray A.
  Assignee(s): Probiodrug
  Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
  
  Patent expiration dates:
  
  
  • April 24, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
  
  



• 
  Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  Patent 6,699,871
  Issued: March 2, 2004
  Inventor(s): Scott D.; Edmondson & Michael H.; Fisher & Dooseop; Kim & Malcolm; Maccoss & Emma R.; Parmee & Ann E.; Weber & Jinyou; Xu
  Assignee(s): Merck &amp; Co., Inc.
  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
  
  Patent expiration dates:
  
  
  • July 26, 2022
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 6,890,898
  Issued: May 10, 2005
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  1149336 Ontario Inc.
  New England Medical Center Hospitals, Inc.
  The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)
  
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
  
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 7,078,381
  Issued: July 18, 2006
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
  
  



• 
  Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  Patent 7,125,873
  Issued: October 24, 2006
  Inventor(s): Edmondson; Scott D & Fisher; Michael H. & Kim; Dooseop & Maccoss; Malcolm & Parmee; Emma R. & Weber; Ann E & Xu; Jinyou
  Assignee(s): Merck &#x26; Co., Inc.
  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
  
  Patent expiration dates:
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
    ✓ 
    Drug product
  
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
    ✓ 
    Drug product
  
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
    ✓ 
    Drug product
  
  
  
  • July 26, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
    ✓ 
    Drug product
  
  



• 
  Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
  Patent 7,326,708
  Issued: February 5, 2008
  Inventor(s): Cypes; Stephen Howard & Chen; Alex Minhua & Ferlita; Russell R. & Hansen; Karl & Lee; Ivan & Vydra; Vicky K. & Wenslow, Jr.; Robert M.
  Assignee(s): Merck &#x26; Co., Inc.
  The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.
  
  Patent expiration dates:
  
  
  • April 11, 2026
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method of regulating glucose metabolism, and reagents related thereto
  Patent 7,459,428
  Issued: December 2, 2008
  Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
  Assignee(s): Trustees of Tufts College
  New England Medical Center Hospitals, Inc.
  1149336 Ontario, Inc.
  One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.
  
  Patent expiration dates:
  
  
  • February 2, 2019
    
    ✓ 
    Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
  
  

See also...

• Juvisync Consumer Information (Drugs.com)
• Juvisync Consumer Information (Wolters Kluwer)
• Juvisync Consumer Information (Cerner Multum)
• Sitagliptin/Simvastatin Consumer Information (Wolters Kluwer)
• Simvastatin and sitagliptin Consumer Information (Cerner Multum)

Tandospirone

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N05B

CAS registry number (Chemical Abstracts Service)

0087760-53-0

Chemical Formula

C21-H29-N5-O2

Molecular Weight

383

Therapeutic Categories

Anxiolytic agent

Antidepressant

Chemical Name

(1R,2S,3R,4S)-N-{4-[4-(Pyrimidin-2-yl)-piperazin-1-yl]butyl}-8,9,10-trinobornane-2,3-dicarboximide (1:1)

Foreign Names

• Tandospironum (Latin)
• Tandospiron (German)
• Tandospirone (French)
• Tandospirona (Spanish)

Generic Names

• Tandospirone (OS: BAN)
• SM 3997 (IS: Sumitomo)
• Tandospirone Citrate (OS: USAN, BANM)

Brand Names

• Sediel
  Dainippon, China; Dainippon Sumitomo, Japan

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Nicotine Transdermal System

Ingredient matches for Nicotine Transdermal System

Nicotine

Nicotine is reported as an ingredient of Nicotine Transdermal System in the following countries:

• United States

International Drug Name Search

Ceglution

Ceglution may be available in the countries listed below.

Ingredient matches for Ceglution

Lithium

Lithium carbonate (a derivative of Lithium) is reported as an ingredient of Ceglution in the following countries:

• Argentina


• Ecuador

International Drug Name Search